Here are the editors' top picks for the week ended July 27.
Smaller biotechs trump Big Pharma CEO compensation in 2017
Two US biotechs with less than $10 billion in market cap paid their CEOs more in 2017 than large-caps such as AbbVie Inc. — maker of the world's best-selling medicine Humira, S&P Global Market Intelligence data shows.
ViiV CEO says the GlaxoSmithKline unit will lead HIV market by mid-2020s
ViiV Healthcare Ltd. CEO Deborah Waterhouse spoke to S&P Global Market Intelligence about the global HIV market, which is growing by 7% to 8% per year, ahead of the unveiling of the full results of the Gemini trials.
Zimmer welcomes new CEO with highest pay in US medtech sector in 2017
Meanwhile, Pulse Biosciences Inc.'s Darrin Uecker got the biggest salary hike among the top 10 highest-paid CEOs of U.S. medical equipment makers in 2017, despite the company widening its net loss year over year, S&P Global Market Intelligence data showed.
Of Mice Not Men: Safer long-term estrogen therapy; extending lifespan in mice
In this week's column, researchers at the University of Illinois discovered that long-term estrogen therapy changes the gut's microbiome, while a study supported by the National Institute on Aging extended the lifespan of old mice.
GlaxoSmithKline pursues Silicon Valley-flavored R&D shake-up with 23andMe
GlaxoSmithKline PLC will partner with consumer genetics company 23andMe Inc. as CEO Emma Walmsley unveiled a new, Silicon Valley-inspired approach to research and development at the pharmaceutical group, driven by biotechnology veteran Hal Barron.
US House probes addiction centers' deceptive marketing, patient brokering
Lawmakers on Capitol Hill pressed operators of addiction treatment centers and their affiliated websites and call centers about whether they have engaged in deceptive marketing campaigns and exploited vulnerable patients.
GSK CEO to set out R&D priorities at Q2 as analysts play down consumer split
At the half-year results to be presented July 25, GlaxoSmithKline CEO Emma Walmsley will lay out her much-anticipated vision for the Brentford-based pharmaceutical giant, with the help of her new head of research, Hal Barron.
UPDATE: Lilly to spin off animal health unit, keep M&A option for core business
Eli Lilly and Co. said it was going to sell a portion of its animal health unit to the public following a strategic review of the business.
CMS: Medicare patients missed $600 million in savings by using branded drugs
Seniors and disabled Americans enrolled in the government's Medicare Part D drug program could have saved over $600 million in out-of-pocket costs had they used generics over brand-name medicines, the Trump administration reported in a new analysis.
Capitol Checkup: Importation reluctance; price pledge optics; gag clause vote
It is unclear if the U.S. Food and Drug Administration chief will back drug importation, and recent pledges to lower medicine prices may do little to reduce Americans' costs.
Court: Allergan cannot use tribal immunity to shield Restasis patent
Allergan PLC and the St. Regis Mohawk Tribe cannot claim sovereign immunity protection to shield a patent on the drug company's dry-eye medicine Restasis from challengers seeking to compete with lower-cost generic versions, a federal court ruled.
Roche lifts 2018 outlook as new medicines help to offset patent expiries in H1
Roche Holding AG raised full-year guidance on the back of strong sales for a swathe of its new medicines, which are helping to offset the impending patent cliff it faces when Herceptin loses exclusivity, starting in the second half of 2018 in Europe.
Amgen readies migraine drug launch ahead of copycat competition for Neulasta
The Thousand Oaks, Calif.-based drugmaker is offering free trials to provide a strong launch pad for its new migraine drug Aimovig as it prepares to compete with a copy of its blockbuster drug Neulasta.
Bristol-Myers banks on Opdivo as EU regulators caution renal cancer application
Bristol-Myers Squibb Co. posted strong results owing to its immuno-oncology franchise during the quarter, even as European regulators gave pause over using the drug in combination to treat front-line renal cancer.
Allergan CEO: no 'fire sale' for women's health, infectious disease units
Allergan PLC is letting go of its women's health and infectious disease units to focus on its four core therapeutic areas — medical aesthetics, central nervous system, eye care and gastroenterology.
Celgene CEO says M&A remains 'top priority,' updates drug pricing principles
CFO Peter Kellogg said the company continues to support growing its pipeline with M&A and business development investments and has deployed over $10 billion on M&A and business development year-to-date.
AstraZeneca CEO sees China leapfrogging Europe with strong drug sales growth
AstraZeneca PLC forecast that China will overtake Europe as a pharmaceutical market, as the U.K. company continues to benefit from advancing sales in the region thanks to a combination of government investment and a faster regulatory process.
Gilead's cell therapies, HIV franchise take center stage as Hep C sales drop
The company's US HIV business continues to be "a major growth driver," with the rapid rise in Biktarvy sales in the second quarter propelling that growth, CFO Robin Washington said on an earnings call.